

**EISAI ONCOLOGY TO PRESENT NEW RESEARCH ON PRODUCT PORTFOLIO,
PIPELINE AT ASCO ANNUAL MEETING**

Eisai Co., Ltd. (Headquarters: Tokyo, President and CEO: Haruo Naito, “Eisai”) announced today that 19 abstracts highlighting new study results on thyroid cancer, acute myeloid leukemia, metastatic breast cancer, ovarian cancer and other cancers will be presented during the 47th Annual Meeting of the American Society of Clinical Oncology (ASCO), taking place in Chicago, United States, from June 3 to June 7, 2011.

These studies highlight Eisai’s current product portfolio and oncology pipeline, reinforcing the company’s commitment to address the diverse needs of patients and their families affected by cancer.

Eisai's commitment to meaningful progress in oncology research, built on scientific expertise, is supported by a global capability to conduct discovery and preclinical research, and develop small molecules, biologics chemotherapies and supportive care agents for cancer across multiple indications. Through these efforts, Eisai will make further contributions to addressing the diversified needs of and increasing the benefits provided to patients and their families as well as healthcare professionals as it seeks to fulfill its human health care (*hhc*) mission.

■ The following Eisai abstracts are accepted for presentation at this year’s ASCO meeting:

	Product	Abstract Details
1	Lenvatinib (E7080) Abstract No:5503	A Phase II Trial of the Multi-Targeted Kinase Inhibitor E7080 in Advanced Radioiodine (RAI)-Refractory Differentiated Thyroid Cancer (DTC) <i>Oral Session</i>
2	Lenvatinib (E7080) Abstract No:8527	Assessment of Clinical Activity of E7080, a Multi-Targeted Kinase Inhibitor, in Patients with Advanced Melanoma Treated in Two Phase I trials <i>Poster discussion session</i>
3	Lenvatinib (E7080) Abstract No: 8566	The Effect of E7080, a VEGFR and FGFR Tyrosine Kinase Inhibitor (TKI), on BRAF Wild-Type Melanoma <i>Poster Session</i>
4	Lenvatinib (E7080) Abstract No:8567	Mechanism of Antitumor Activity of E7080, a Selective VEGFR and FGFR Tyrosine Kinase Inhibitor (TKI) in Combination with Selective Mutant BRAF Inhibition <i>Poster Session</i>
5	Lenvatinib (E7080) Abstract No:8595	Molecular profiling of melanoma tumor biopsies to identify a response signature to the multi-RTK inhibitor, E7080 <i>Poster Presentation</i>
6	Farletuzumab (MORAb-003) Abstract No:5056	Phase I Safety Study of Farletuzumab, Carboplatin and Peglyated Liposomal Doxorubicin (PLD) in Subjects with Platinum-Sensitive Epithelial Ovarian Cancer (EOC) <i>Poster Session</i>
7	MORAb-004 Abstract No:3086	A First-in-Human Phase I Study of MORAb-004 (MOR4), a humanized monoclonal antibody recognizing TEM-1 (endosialin), in patients with solid tumors <i>Poster Session</i>
8	Decitabine for Injection Abstract No: 6504	Results from a Randomized Phase III Trial of Decitabine Versus Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients with Newly Diagnosed AML <i>Oral Session</i>

(Continued on the following page)

9	Decitabine for Injection Abstract No:6551	Population Pharmacokinetic modeling of Decitabine in Patients with Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) <i>Poster Session</i>
10	Decitabine for Injection Abstract No:6552	Healthcare utilization and costs in patients with early onset myelodysplastic syndrome in a commercially insured population <i>Poster Session</i>
11	Decitabine for Injection Abstract No:6560	Relationship Between Age and Healthcare Utilization in Patients with Myelodysplastic Syndrome Receiving Supportive Care <i>Poster Session</i>
12	Decitabine for Injection Abstract No:6598	Retrospective Analysis of Prognostic Factors Associated with Response and Overall Survival in Patients with RAEB-t MDS treated with Decitabine <i>Poster Session</i>
13	Decitabine for Injection Abstract No:6600	Retrospective analysis of effects of dose modification and myelosuppression on response to decitabine and overall survival in patients with myelodysplastic syndromes. <i>Poster Session</i>
14	Decitabine for Injection Abstract No:6617	Retrospective Analysis of Effects of Transfusion Status on Response to Decitabine and Survival in Patients with Myelodysplastic Syndromes <i>Poster Session</i>
15	Eribulin Mesylate Abstract No: 1060	The Relationship Between Age and Survival Outcomes for Eribulin in Metastatic Breast Cancer <i>Poster Session</i>
16	Eribulin Mesylate Abstract No: 2544	Eribulin Dosing in Patients with Advanced Solid Tumors and Hepatic Impairment <i>Poster Session</i>
17	Palonosetron Hydrochloride Abstract No:9091	Analysis of Phase III Clinical Studies for Palonosetron, Ondansetron, Dolasetron and Granisetron in the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) <i>Poster Session</i>
18	Palonosetron Hydrochloride Abstract No:6068	Willingness to Pay to Prevent Chemotherapy Induced Nausea and Vomiting <i>Poster Session</i>
19	Polifeprosan 20 with carmustine implant Abstract No:2015	Effects of Surgery with BCNU Wafer Placement on Neurocognitive Function in Patients with One to Three Brain Metastases <i>Poster Discussion</i>

Decitabine = Dacogen[®] , Eribulin Mesylate = Halaven[®] , Palonosetron Hydrochloride = Aloxi[®] , Polifeprosan 20=Gliadel[®] Wafer

Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120